Current Psychiatry Reports

, Volume 13, Issue 6, pp 467–475 | Cite as

Is Depression an Inflammatory Disorder?

Unipolar Disorders (Michael E. Thase, Section Editor)

Abstract

Studies consistently report that groups of individuals with major depressive disorder (MDD) demonstrate increased levels of a variety of peripheral inflammatory biomarkers when compared with groups of nondepressed individuals. These findings are often interpreted as meaning that MDD, even in medically healthy individuals, may be an inflammatory condition. In this article, we examine evidence for and against this idea by looking more closely into what the actual patterns of inflammatory findings indicate in terms of the relationship between MDD and the immune system. Data are presented in support of the idea that inflammation only contributes to depression in a subset of patients versus the possibility that the depressogenic effect of inflammatory activation is more widespread and varies depending on the degree of vulnerability any given individual evinces in interconnected physiologic systems known to be implicated in the etiology of MDD. Finally, the treatment implications of these various possibilities are discussed.

Keywords

Major depression Fatigue Immune Inflammation Cytokines Interleukin-6 Tumor necrosis factor-α p38 mitogen-activated kinase Psychosocial stress Glucocorticoids Autonomic nervous system Tryptophan Kynurenine Quinolinic acid 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun. 2011;25:221–9.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Connor MF, Bower JE, Cho HJ, et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009;23:887–97.PubMedCrossRefGoogle Scholar
  3. 3.
    De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol. 2010;23:417–22.PubMedGoogle Scholar
  4. 4.
    Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.PubMedCrossRefGoogle Scholar
  7. 7.
    Zorilla E, Luborsky L, McKay J, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199–226.CrossRefGoogle Scholar
  8. 8.
    • Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010;197:372–7. This study was among the first to demonstrate that inflammatory biomarkers predict future depressive status, which is consistent with a causal role for inflammatory processes in the development of depression, even in the absence of documented medical illness. PubMedCrossRefGoogle Scholar
  9. 9.
    Vaccarino V, Johnson BD, Sheps DS, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol. 2007;50:2044–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Progr Neuropsychopharmacol Biol Psychiatry. 2007;31:370–2.CrossRefGoogle Scholar
  11. 11.
    Liukkonen T, Silvennoinen-Kassinen S, Jokelainen J, et al. The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth cohort study. Biol Psychiatry. 2006;60:825–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J. 2004;25:492–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65:347–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.PubMedCrossRefGoogle Scholar
  15. 15.
    Vidula H, Tian L, Liu K, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med. 2008;148:85–93.PubMedGoogle Scholar
  16. 16.
    Ridker PM. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65:S253–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61:824–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Laurin D, David Curb J, Masaki KH, et al. Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up. Neurobiol Aging. 2009;30:1724–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Capuron L, Fornwalt FB, Knight BT, et al. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord. 2009;119:181–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric side effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:1–19.CrossRefGoogle Scholar
  23. 23.
    Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol. 2002;26:643–52.CrossRefGoogle Scholar
  25. 25.
    Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun. 2009;23:1109–16.PubMedCrossRefGoogle Scholar
  26. 26.
    Raison CL, Borisov AS, Woolwine BJ, et al. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010;15:535–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Dunn AJ, Wang J. Cytokine effects on CNS biogenic amines. Neuroimmunomodulation. 1995;2:319–28.PubMedCrossRefGoogle Scholar
  28. 28.
    Schafer A, Scheurlen M, Seufert J, et al. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. J Hepatol. 2010;52:10–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003;160:1342–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Wright CE, Strike PC, Brydon L, Steptoe A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. 2005;19:345–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Eisenberger NI, Inagaki TK, Mashal NM, Irwin MR. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun. 2010;24:558–63.PubMedCrossRefGoogle Scholar
  33. 33.
    • Eisenberger NI, Berkman ET, Inagaki TK, et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010;68:748–54. This study demonstrated that acute exposure to lipopolysaccharide reduces ventral striatal responses to rewarding stimuli, which associates with induction of anhedonia in otherwise nondepressed individuals. This finding collaborates with other data demonstrating a tropism of proinflammatory cytokines for the basal ganglia, and demonstrates that cytokines are capable of producing brain changes observed frequently in MDD. PubMedCrossRefGoogle Scholar
  34. 34.
    Harrison NA, Brydon L, Walker C, et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry. 2009;66:415–22.PubMedCrossRefGoogle Scholar
  35. 35.
    •• Harrison NA, Brydon L, Walker C, et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66:407–14. This was a seminal paper showing that typhoid vaccine induces depressed mood independent of changes in the cingulate cortex that are also commonly observed in MDD. PubMedCrossRefGoogle Scholar
  36. 36.
    Brydon L, Harrison NA, Walker C, et al. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry. 2008;63:1022–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Capuron L, Pagnoni G, Demetrashvili MF, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacol. 2007;32:2384–92.CrossRefGoogle Scholar
  38. 38.
    Capuron L, Pagnoni G, Demetrashvili M, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry. 2005;58:190–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2008;39:413–23.PubMedCrossRefGoogle Scholar
  40. 40.
    Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–30.PubMedCrossRefGoogle Scholar
  41. 41.
    Miller GE, Freedland KE, Carney RM, et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun. 2003;17:276–85.PubMedCrossRefGoogle Scholar
  42. 42.
    Ranjit N, Diez-Roux AV, Shea S, et al. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch Intern Med. 2007;167:174–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Dai J, Miller AH, Bremner JD, et al. Adherence to the Mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation. 2008;117:169–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Zampelas A, Panagiotakos DB, Pitsavos C, et al. Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: the ATTICA study. J Am Coll Cardiology. 2005;46:120–4.CrossRefGoogle Scholar
  45. 45.
    Irwin MR, Wang M, Campomayor CO, et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med. 2006;166:1756–62.PubMedCrossRefGoogle Scholar
  46. 46.
    McDade TW, Hawkley LC, Cacioppo JT. Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago Health, Aging, and Social Relations study. Psychosom Medicine. 2006;68:376–81.CrossRefGoogle Scholar
  47. 47.
    Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Bailey MT, Kinsey SG, Padgett DA, et al. Social stress enhances IL-1beta and TNF-alpha production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells. Physiol Behav. 2009;98:351–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163:1630–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry. 2008;64:896–900.PubMedCrossRefGoogle Scholar
  51. 51.
    Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharm Ther. 2005;22:101–10.CrossRefGoogle Scholar
  52. 52.
    Anisman H, Gibb J, Hayley S. Influence of continuous infusion of interleukin-1beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacol (Berl). 2008;199:231–44.CrossRefGoogle Scholar
  53. 53.
    Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12:988–1000.PubMedCrossRefGoogle Scholar
  54. 54.
    Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.PubMedCrossRefGoogle Scholar
  55. 55.
    • Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2011, Epub. This is a comprehensive review of known data supporting a role for inflammation in the pathophysiology and treatment of MDD. Google Scholar
  56. 56.
    Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010;167:509–27.PubMedCrossRefGoogle Scholar
  57. 57.
    Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry. 2008;14:1095–104.PubMedCrossRefGoogle Scholar
  58. 58.
    Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554–65.PubMedCrossRefGoogle Scholar
  59. 59.
    Vaccarino V, Lampert R, Bremner JD, et al. Depressive symptoms and heart rate variability: evidence for a shared genetic substrate in a study of twins. Psychosom Med. 2008;70:628–36.PubMedCrossRefGoogle Scholar
  60. 60.
    Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64:527–32.PubMedCrossRefGoogle Scholar
  61. 61.
    Masten CL, Eisenberger NI, Borofsky LA, et al. Subgenual anterior cingulate responses to peer rejection: a marker of adolescents’ risk for depression. Dev Psychopathol. 2011;23:283–92.PubMedCrossRefGoogle Scholar
  62. 62.
    Sheline YI, Barch DM, Price JL, et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci USA. 2009;106:1942–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957–66.PubMedCrossRefGoogle Scholar
  64. 64.
    Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66:1050–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105–23.PubMedCrossRefGoogle Scholar
  66. 66.
    Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011;18:153–60.PubMedCrossRefGoogle Scholar
  67. 67.
    • Felger JC, Alagbe O, Pace TW, et al. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun. 2011, Epub. This study demonstrated that activity in inflammation-related intracellular signaling cascades in response to an initial inflammatory stimulus (IFN-α) strongly predicts the later development of depressive symptoms during chronic cytokine exposure. Google Scholar
  68. 68.
    Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003;160:1342–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Robaeys G, De Bie J, Wichers MC, et al. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J Gastroenterol. 2007;13:5736–40.PubMedGoogle Scholar
  70. 70.
    Wichers MC, Koek GH, Robaeys G, et al. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med. 2005;35:433–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Wichers MC, Kenis G, Koek GH, et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res. 2007;62:207–14.PubMedCrossRefGoogle Scholar
  72. 72.
    Kenis G, Prickaerts J, van Os J, et al. Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 2011;14:247–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–14.PubMedCrossRefGoogle Scholar
  74. 74.
    Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468–73.PubMedCrossRefGoogle Scholar
  75. 75.
    Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86–90.PubMedCrossRefGoogle Scholar
  76. 76.
    •• Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393–403. Data in this article support a recent conceptual shift in the role of tryptophan metabolism in the etiology of depression from a focus on reduced serotonin to increased catabolites along the kynurenine pathway. PubMedCrossRefGoogle Scholar
  77. 77.
    Raison CL, Rye DB, Woolwine BJ, et al. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry. 2010;68:942–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Wichers MC, Kenis G, Leue C, et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry. 2006;60:77–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.PubMedCrossRefGoogle Scholar
  80. 80.
    Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.PubMedCrossRefGoogle Scholar
  81. 81.
    Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26:607–11.PubMedCrossRefGoogle Scholar
  82. 82.
    Wang Y, Yang F, Liu YF, et al. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett. 2011, Epub.Google Scholar
  83. 83.
    Brunello N, Alboni S, Capone G, et al. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol. 2006;21:219–25.PubMedCrossRefGoogle Scholar
  84. 84.
    Mendlewicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol. 2006;21:227–31.PubMedCrossRefGoogle Scholar
  85. 85.
    Zautra AJ, Davis MC, Reich JW, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol. 2008;76:408–21.PubMedCrossRefGoogle Scholar
  86. 86.
    Balducci S, Zanuso S, Nicolucci A, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis. 2009;20:608–17.PubMedCrossRefGoogle Scholar
  87. 87.
    Kohut ML, McCann DA, Russell DW, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006;20:201–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Blumenthal JA, Sherwood A, Babyak MA, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005;293:1626–34.PubMedCrossRefGoogle Scholar
  89. 89.
    Pace TW, Negi LT, Sivilli TI, et al. Innate immune, neuroendocrine and behavioral responses to psychosocial stress do not predict subsequent compassion meditation practice time. Psychoneuroendocrinol. 2010;35:310–5.CrossRefGoogle Scholar
  90. 90.
    Pace TW, Negi LT, Adame DD, et al. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinol. 2009;34:87–98.CrossRefGoogle Scholar
  91. 91.
    Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Mind-Body Program; Department of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlantaUSA

Personalised recommendations